Experience with eosin-5'-maleimide as a diagnostic tool for red cell membrane cytoskeleton disorders.
The diagnosis of hereditary spherocytosis (HS) is based on red cell morphology and other conventional tests such as osmotic fragility, autohemolysis and acidified glycerol lysis. However, milder cases are at times difficult to diagnose. Confirmation by red blood cell (RBC) membrane protein analysis is not possible in most laboratories. Recently, a flow cytometric method has been described for quantitating the fluorescence intensity of intact red cells after incubation with the dye eosin-5'-maleimide (EMA), which binds specifically to the anion transport protein (band-3) at lysine-430. This has been shown to be an effective screening test for red cell membrane disorders. We evaluated the usefulness of this approach for screening membrane protein disorders such as HS and hereditary elliptocytosis (HE) and its value in discriminating this group from other hemolytic anemias, such as glucose-6-phosphate dehydrogenase (G6PD) deficiency, beta-thalassemia trait, sickle cell anemia and autoimmune hemolytic anemia. Fluorescence intensity, expressed in mean channel fluorescence (MCF) units, was determined using a Becton Dickinson FACS Caliber flow cytometer. Membrane protein analysis was carried out by sodium dodecyl sulfate-polyacrylamide gel eletrophoresis (SDS-PAGE). RBCs from patients with HS and HE gave significantly lower MCF values (P < 0.001) than the normal control group and other patient groups. The diagnosis of HS in four cases was confirmed by RBC membrane protein electrophoresis and all showed a deficiency of spectrin. The advantage of the EMA dye method are its specificity for membrane disorders, as well as being a simple, user-friendly and rapid method which is inexpensive, provided a flow cytometer is available.
Kedar
P S
PS
Institute of Immunohaematology (Indian Council of Medical Research), KEM Hospital Campus, Parel, Mumbai, India.
Colah
R B
RB
Kulkarni
S
S
Ghosh
K
K
Mohanty
D
D
D000293:Adolescent; D000328:Adult; D000743:Anemia, Hemolytic / Q000145:classification / Q000175:diagnosis; D001457:Anion Exchange Protein 1, Erythrocyte / Q000032:analysis / Q000187:drug effects; D001797:Blood Protein Electrophoresis; D002648:Child; D002675:Child, Preschool; D004396:Coloring Agents / Q000494:pharmacology; D003599:Cytoskeleton / Q000648:ultrastructure*; D003937:Diagnosis, Differential; D004612:Elliptocytosis, Hereditary / Q000097:blood / Q000175:diagnosis* / Q000473:pathology; D004801:Eosine Yellowish-(YS) / Q000031:analogs & derivatives* / Q000494:pharmacology; D004910:Erythrocyte Membrane / Q000737:chemistry / Q000648:ultrastructure*; D005260:Female; D005434:Flow Cytometry / Q000379:methods*; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D013049:Spectrin / Q000032:analysis / Q000172:deficiency; D013103:Spherocytosis, Hereditary / Q000097:blood / Q000175:diagnosis* / Q000473:pathology; D013194:Staining and Labeling / Q000379:methods*
D001457:Anion Exchange Protein 1, Erythrocyte; D004396:Coloring Agents; D013049:Spectrin; C033531:eosin maleimide; D004801:Eosine Yellowish-(YS)